Group items tagged

Having children interrupt your sleep may not be the cause of your daytime drowsiness. You may be one of the 80% of women in the U.S. reported to have adrenal gland fatigue. If you have never heard of the adrenal gland or...

CP Child Wheelchair Cerebral palsy (CP) is a disorder of the brain. Normally, the brain tells the rest of the body exactly what to do and when to do it.CP affects the brain, a person might not be able to walk, talk, eat, or move the way most people do. CP affects a person's muscle tone and ability to coordinate body movements. People with CP have trouble controlling their muscles. CP affects the part of the brain that controls speech, a person with CP might have trouble talking clearly or not be able to speak at all. Because cerebral palsy affects muscle control, some people have learning disabilities or behavior problems - though many people with CP don't have these issues. Other people with CP also have medical problems like seizures or epilepsy, or hearing impairment. CP may work with these experts: a pediatric orthopedist a developmental pediatrician who looks at how the person is growing or developing compared with other teens a pediatric physiatrist (or rehabilitation physician), who helps kids with disabilities of many kinds therapists, like physical therapists to help with movement, occupational therapists to help with skills like handwriting, and speech therapists Features Ultra light weight aluminum alloy frame Epoxy powder coated frame Detachable arm rest provided Height adjustable and detachable head rest Hydraulic reclining high back for a comfortable posture Detachable back and seat pad Extra cushion upholstery provided to under arm, head. Hand brakes provided Safety belt provided Cerebral Palsy Wheelchair Price Cerebral Palsy is a long-term chronic medical condition that requires long-term supportive care services.Cerebral Palsy often have other associative and co-mitigating medical conditions, including cognitive challenges, vision loss, hearing impairment, and seizures. These conditions require diagnosis, treatment and maintenance all at significant cost.The family of an individual with cerebral palsy is like

Types of CP Associated With Muscle Tone Cerebral palsy comes in several types, which may be associated with muscle tone or specific body parts. Those associated with muscle tone include: spastic CP, where abnormally high muscle tone causes problems with movement, usually in the legs and hips; ataxia, which is marked by involuntary muscle movements; athetoid, which prevents sufferers from maintaining a fixed muscle position (for example, grasping and holding); and mixed, where symptoms of both spastic and athetoid CP occur. Cerebral Palsy: Hope Through Research: Detailed information from the National Institute of Neurological Disorders and Stroke, including facts on the causes, risk factors, warning signs, and types of CP. Definitions and Accommodations for Cerebral Palsy: Information on the types of CP and how to accommodate and interact with severe sufferers. From Kentucky's Office for the Americans With Disabilities Act. United Cerebral Palsy Association: Nonprofit organization that offers a nationwide network of affiliates aimed at expanding the rights, freedoms, and opportunities of those with cerebral palsy. Health Encyclopedia: Cerebral Palsy: Facts on the types, causes, prevalence, and accommodations related to cerebral palsy. Provided by the Florida Agency for Health Care Administration. Cost of Cerebral Palsy: Information on the human and economic impact of cerebral palsy, presented in the form of an academic report composed by the Environmental Protection Agency. Types of CP Associated With Body Parts Certain types of cerebral palsy are associated with specific body parts rather than with the general condition of the muscular system. These types include: quadriplegia, in which all four limbs suffer severe motor dysfunction and a general inability to work together; hemiplegia, in which the limbs on one side of the body are severely affected, with the impact more pronounced in the digits; and diplegia, which causes problems with mus

Medical robots are increasingly being adopted by hospitals and patients across the globe, particularly in the U.S. Demographic change, shortage of healthcare professionals, need to improve quality of life for the disabled and elderly, and need to improve surgical procedures coupled with the focus to develop technologically advanced robots are some of the factors expected to stimulate growth the adoption of medical robots.

MedsDelta provides Sunitinib Capsules by Pfizer makes under trade name Sutent capsules, availing at a reasonable price. Sunitinib is for treating a specific sort of stomach, gut, or throat tumor in specific patients. It is additionally used to treat certain sorts of kidney or pancreatic tumor. #MedsDelta exporting Generic Sunitinib Capsules across all over the world, countries like U.K., U.S, Nepal, Philippines, China, Japan, Singapore, Romania, Vietnam, Canada, Hongkong, Russia, and over 150 countries. We at MedsDelta, supplying Generic #Sunitinib Medicines at reasonable prices and giving you accurate information about the product. If you want to order Generic Sunitinib Capsules - #Sutent25mg Capsules, you can contact us anytime 24*7 at -> +91-9971646666, QQ: 3451266709, Skype: medsdelta, WeChat: medsdelta, or mail: medsdelta@gmail.com. We ensure to provide our best services and authentic medication.

Dr. Michael Omidi MD, along with his brother Julian Omidi, is cofounder of No More Poverty, an organization promoting the works of charities that strive to end poverty and the conditions that cause poverty both in the U. S. and abroad. In this article, Dr. Michael Omidi discusses the Omidi brothers' sponsorship of Jessica's Hope Project, a foundation that sends healthy care packages to U.S. soldiers overseas.

Researchers from the University of Oxford today (December 8) started recruiting for a clinical trial to test novel antiviral Covid-19 treatments for early use in the illness by people in the community and those who are at higher risk of complications. Partnering with the National Institute for Health Research (NIHR), colleagues in several UK universities, and the NHS UK-wide, the Platform Adaptive trial of NOvel antiviRals for eArly treatMent of Covid-19 In the Community (PANORAMIC), is a national priority trial, and will be open to participants from across the UK. The first treatment to be tested by the UK Antiviral Taskforce will be molnupiravir, a Covid antiviral pill already licensed by the MHRA. Britain became the first country in the world to approve molnupiravir, which was jointly developed by U.S.-based Merck & Co Inc and Ridgeback Biotherapeutics, in November.

Despite significant sales growth in the quarterly results, high street chemist Boots is moving forward with its plan to close 300 stores in the UK. The move, aimed at improving profit margins amid rising costs and competition, will reduce the chain's portfolio from around 2,200 to just 1,900. Last month, the U.S.-based Walgreens Boots Alliance, the parent company of Boots, announced upcoming store closures within the next year. However, the company assured that there will be no job losses as all employees will be given the opportunity to be redeployed to nearby shops. The following sites are confirmed for closure on the specified dates: Heathside Rd, Woking (end of July) UEA campus (end of July) Hamlet Ct Rd, Westcliff-on-Sea (August 1) Windhill Road, Wakefield (October 6) Upper Warrengate, Wakefield (October 7) Glastonbury (October 13) Guildford Road, Woking (end of October) Boots stores at Salford Shopping Centre in Greater Manchester, Church Street in Malvern, The Port Arcades Shopping Centre in Ellesmere, and King William Street in London have already closed since spring.

Capitalising on strong demand for its obesity therapies, Novo Nordisk's growing appetite for deals has fuelled a bet on a U.S. gene-editing company called Life Edit Therapeutics. The Danish drugmaker's collaboration with Durham, North Carolina-based Life Edit Therapeutics - owned by ElevateBio, a cell and gene therapy company in Waltham - is focused on up to seven programs for rare genetic disorders as well as cardiometabolic diseases. At the heart of the tie-up is Life Edit's technology, called base editing, which is designed to make precise changes to the human genome by tweaking one base - or letter - into a different one without affecting other letters. Single-letter mistakes, called point mutations, can give rise to genetic diseases.

Britain plans to launch a pilot programme exploring how new weekly weight-loss shots such as Novo Nordisk's Wegovy can be given to obese patients by general practitioners even as the drug's market launch remains unclear. The government's announcement on the £40 million pilot programme comes after drug cost-effectiveness watchdog NICE in March recommended the use of Wegovy in adults with at least one weight-related condition and a body mass index of 35, but only within the NHS specialist weight management scheme. The timing of Wegovy's launch in Britain - which would be only the fourth country to use it - is uncertain, however, after Novo last month rationed starter doses to secure supply to U.S. patients already on the regimen, after it was overwhelmed by demand there. British Prime Minister Rishi Sunak said on Wednesday (May 7) the pilot and fighting obesity-related diseases could reduce pressure on hospitals. It would also support "people to live healthier and longer lives, and helping to deliver on my priority to cut NHS waiting lists". The NHS endured a tough winter in England in particular, with waiting lists hitting record highs and staff striking for higher pay amid double-digit inflation.

The widely-held concept that levels of "good" cholesterol in the blood can indicate heart disease risk is not equally true for Blacks and whites, and the measure itself may be of less value than previously thought, according to a U.S. study published on Monday (November 21). Various types of cholesterol are thought to have either healthy or unhealthy effects. Low levels of so-called "good" high-density lipoprotein (HDL) cholesterol were linked with higher odds for developing cardiac problems in the long-term study - but only in white participants, the study published in the Journal of the American College of Cardiology found. In contradiction to what has generally been assumed, low HDL levels did not confer any higher risk of heart disease in Black people, researchers said. Among white people, however, those with HDL levels below 40 milligrams per deciliter had a 22% higher risk for coronary heart disease compared with those whose HDL levels were higher. High HDL levels (above 60 mg/dL), which are thought to be protective, were not linked with lower coronary heart disease risks in either race, researchers found.

Sun Pharma has announced that it will acquire all outstanding shares of Concert Pharmaceuticals through a tender offer for an upfront payment of $8.00 per share of common stock in cash, or $576 million in equity value. The upfront payment of $8.00 per share of common stock in cash represents a premium of approximately 33% to Concert's 30-day volume weighted average price as of January 18, 2023, the last trading day prior to today's announcement. Concert is a late-stage biotechnology company pioneering the use of deuterium in medicinal chemistry. Concert has an extensive patent portfolio, including its lead product candidate deuruxolitinib - an oral inhibitor of Janus kinases JAK1 and JAK2 for the treatment of Alopecia Areata, an autoimmune dermatological disease - which is in late-stage development. It has completed the evaluation of the efficacy and safety of deuruxolitinib in adult patients with moderate to severe Alopecia Areata in its THRIVE-AA Phase 3 clinical program and two open label, long-term extension studies are ongoing in North America and Europe. Sun Pharma's immediate focus would be to follow Concert's plan to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the first half of 2023.

New GSK raised its 2022 forecast for the second time this year, after third-quarter earnings and sales topped estimates, continuing its strong start as a standalone prescription medicine and vaccine business since carving out its consumer health division Haleon. After years of underperformance relative to its peers and missing out on the lucrative market for the first set of COVID-19 vaccines, GSK has delivered a string of strong results. The latest is led by a record quarter for its blockbuster shingles vaccine Shingrix and higher-than-expected revenue from its COVID therapy, Xevudy. Having survived a revolt by activist investors Elliott and Bluebell last year, GSK's prospects have been boosted by clinical trial success, though concerns remain around U.S. litigation over heartburn drug Zantac. Thousands of lawsuits have been filed in the United States against a raft of drugmakers over allegations the heartburn drug contains a probable carcinogen.

British drugmaker AstraZeneca said on Thursday (June 1) it would stop developing its drug brazikumab to treat inflammatory bowel diseases, including Crohn's disease and ulcerative colitis. The company said the discontinuation was due to a delay in the drug's development timeline, affected by global events and "the context of a competitive landscape". AstraZeneca regained the rights to brazikumab from Allergan in 2020 following U.S. drugmaker AbbVie's $63 billion tie-up with Allergan. AbbVie will stop funding the drug's development, AstraZeneca said. AbbVie's Skyrizi also treats Crohn's disease.

AstraZeneca said on Monday (June 27) two of its existing therapies were recommended for treating patients with some forms of high-risk breast cancers in the European Union, in a boost to the company's oncology portfolio. Lynparza, a cancer drug developed jointly with U.S.-based Merck, was backed for standalone use or in combination with endocrine therapy in adults with a form of genetically mutated early-stage breast cancer. The drug, which has received a similar recommendation in the United States in March, is a key asset for AstraZeneca. It was recommended in patients with low-to-normal levels of a protein known as HER2 that is the target of several new therapies. Enhertu - developed jointly with Japan's Daiichi Sankyo (4568.T) - was the other drug that was endorsed by the European Medicines Agency for treating an aggressive form of breast cancer characterised by a high rate of HER2.

American biotechnology company Novavax said on Monday (February 28) it would pursue full approval of its Covid-19 vaccine in the second half of this year and forecast total revenue of between $4 billion and $5 billion for 2022. "We expect to gain additional authorizations where we have already filed, including in the US. We will pursue full approval of our vaccine including filing our BLA (biologics license application), in the second half of 2022," CEO Stanley Erck said during a post-earnings call. Novavax late last month filed for emergency use authorization of the shot in U.S. adults, a much-awaited step following months of struggles with development and manufacturing problems. Novavax said it has completed delivery of around nine million vaccine doses to Indonesia, 6 million to Australia and two million to South Korea and expects to supply 69 million doses to Europe in the first half of this year.

Pfizer said on Tuesday it will pay $11.6 billion to buy Biohaven Pharmaceuticals, making a big bet on its ability to boost sales of the top-selling pill in a new class of migraine drugs. The boards of both companies have approved the deal, they said. Biohaven shares jumped 70 per cent to $141.31, while Pfizer was up slightly at $48.83. Pfizer is flush with cash from a once-in-a-lifetime surge in revenue from Covid-19 vaccines and therapeutics and has said it is looking to buy companies or drugs that could add at least $25 billion in annual sales by the end of the decade. "The CGRP oral medications, though still somewhat newer entrants in a deeply entrenched space, continue to make steady inroads in disrupting the broader migraine market in the U.S.," said BioHaven chief executive Vlad Coric. Biohaven forecast Nurtec sales of $825 million to $900 million in 2022. Pfizer said it expects the pills to eventually overtake the shots.

Clinical trials for BioNTech's cancer vaccines should start this year in Britain, marking an important step towards their possible sale on the open market, the German company's top executive Ugur Sahin told magazine Der Spiegel. BioNTech, known for its COVID vaccine with U.S. partner Pfizer, is currently deciding which types of cancer it wants to test its personalized cancer immunotherapies on and the locations where it will conduct the trials, Sahin said. The company wants these therapies, which are based on messenger RNA (mRNA) technology similar to the one that underpins its COVID-19 vaccine, to soon become a regular treatment for cancer patients. "We believe that this should be possible for large amounts of patients before 2030," Sahin said.

AstraZeneca on Wednesday (April 5) said a combination of its cancer drugs Imfinzi and Lynparza met the main goal in a late-stage trial in patients with advanced ovarian cancer. The drugmaker said treatment with a combination of those drugs, along with chemotherapy and bevacizumab - the existing standard of care - improved progression-free survival in newly diagnosed patients with advanced ovarian cancer without certain mutations. Lynparza is jointly developed with U.S.-based Merck & Co as a treatment for breast cancer in early stage with certain mutations. Imfinzi alone, along with chemotherapy and bevacizumab, did not reach statistical significance in its interim analysis, the drugmaker added. Philipp Harter, director, Department of Gynaecology and Gynaecologic Oncology, Evangelische Kliniken Essen-Mitte, Germany and principal investigator for the trial, said: "DUO-O showcases the power of academia and industry collaboration in advancing new treatment combinations for patients with ovarian cancer. I'm grateful for the academic cooperative study groups and patients around the world that made this trial possible and look forward to sharing the results with the clinical community." Susan Galbraith, executive vice president, Oncology R&D, AstraZeneca, said: "While there has been significant progress for patients with advanced ovarian cancer, an unmet need still remains. These data from the DUO-O trial provide encouraging evidence for this this Lynparza and Imfinzi combination in patients without tumour BRCA mutations and reinforce our continued commitment to finding new treatment approaches for these patients. It will be important to understand the key secondary endpoints as well as data for relevant subgroups."